CATTANEO, DANIELE
CATTANEO, DANIELE
Dipartimento di Oncologia ed Emato-Oncologia
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
2024 T. Barbui, A. Carobbio, V. De Stefano, A. Alvarez-Larran, A. Ghirardi, G. Carioli, F. Fenili, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, L. Calabresi, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Ramundo, F. Lunghi, L. Scaffidi, C. Bucelli, D. Cattaneo, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi, A.M. Vannucchi
The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective
2024 C. Pescia, G. Lopez, D. Cattaneo, C. Bucelli, U. Gianelli, A. Iurlo
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
2024 O. Mulas, E. Abruzzese, L. Luciano, A. Iurlo, I. Attolico, F. Castagnetti, S. Galimberti, M. Bonifacio, M. Annunziata, A. Gozzini, E.M. Orlandi, F. Stagno, G. Binotto, P. Pregno, C. Fozza, M. Loi, M.M. Trawinska, F. De Gregorio, D. Cattaneo, F. Albano, M. Iezza, C. Baratè, L. Scaffidi, C. Elena, V. Giai, E. Scalzulli, M. Breccia, G. La Nasa, G. Caocci
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
2024 F. Palandri, G.A. Palumbo, G. Benevolo, A. Iurlo, E.M. Elli, E. Abruzzese, N. Polverelli, M. Tiribelli, G. Auteri, A. Tieghi, G. Caocci, G. Binotto, F. Cavazzini, F. Branzanti, E. Beggiato, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, L. Scaffidi, M. Venturi, A. Duminuco, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, M.M. Trawinska, N. Vianelli, M. Cavo, M. Bonifacio, M. Breccia
Neutrophilic and eosinophilic dermatoses associated with hematological malignancy
2024 C.A. Maronese, F. Derlino, C. Moltrasio, D. Cattaneo, A. Iurlo, A.V. Marzano
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
2024 F. Palandri, G. Auteri, E. Abruzzese, G. Caocci, M. Bonifacio, F. Mendicino, R. Latagliata, A. Iurlo, F. Branzanti, B. Garibaldi, M.M. Trawinska, D. Cattaneo, M. Krampera, O. Mulas, E.A. Martino, M. Cavo, N. Vianelli, S. Impera, F. Efficace, F. Heidel, M. Breccia, E.M. Elli, G.A. Palumbo
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis
2024 V. Abbonante, A.I. Karkempetzaki, C. Leon, A. Krishnan, N. Huang, C.A. Di Buduo, D. Cattaneo, C.M. Ward, S. Matsuura, I. Guinard, J. Weber, A. De Acutis, G. Vozzi, A. Iurlo, K. Ravid, A. Balduini
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort
2023 D. Cattaneo, C. Bucelli, A. Marchetti, M. Lionetti, E. Fermo, V. Bellani, C. De Magistris, A. Maeda, A. Marella, M. Primignani, D. Consonni, U. Gianelli, A. Neri, L. Baldini, N. Bolli, A. Iurlo
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
2023 F. Palandri, E.M. Elli, G. Auteri, M. Bonifacio, G. Benevolo, F.H. Heidel, S. Paglia, M.M. Trawinska, C. Bosi, E. Rossi, M. Tiribelli, A. Tieghi, A. Iurlo, N. Polverelli, G. Caocci, G. Binotto, F. Cavazzini, E. Beggiato, D. Cilloni, C. Tatarelli, F. Mendicino, M. Miglino, M. Bocchia, M. Crugnola, C. Mazzoni, A.D. Romagnoli, G. Rindone, S. Ceglie, A. D'Addio, E. Santoni, D. Cattaneo, D. Bartoletti, R.M. Lemoli, M. Krampera, A. Cuneo, G.C. Semenzato, R. Latagliata, E. Abruzzese, N. Vianelli, M. Cavo, A. Andriani, V. De Stefano, G.A. Palumbo, M. Breccia
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
2023 F. Palandri, M. Breccia, C. Mazzoni, G. Auteri, E.M. Elli, M.M. Trawinska, N. Polverelli, M. Tiribelli, G. Benevolo, A. Iurlo, A. Tieghi, F.H. Heidel, G. Caocci, E. Beggiato, G. Binotto, F. Cavazzini, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, M. Biondo, M. Venturi, L. Scaffidi, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, E. Abruzzese, D. Bartoletti, S. Paglia, N. Vianelli, M. Cavo, M. Bonifacio, G.A. Palumbo
Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs
2023 A. Iurlo, C. Bucelli, D. Cattaneo
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies
2023 A. Iurlo, D. Cattaneo, C. Bucelli, P. Spallarossa, F. Passamonti
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
2023 A. Iurlo, D. Cattaneo
Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
2023 A. Iurlo, N. Galli, C. Bucelli, S. Artuso, D. Consonni, D. Cattaneo
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
2023 A. Iurlo, D. Cattaneo, D. Consonni, F. Castagnetti, M.C. Miggiano, G. Binotto, M. Bonifacio, G. Rege-Cambrin, M. Tiribelli, F. Lunghi, A. Gozzini, P. Pregno, E. Abruzzese, I. Capodanno, C. Bucelli, M. Pizzuti, S. Artuso, M. Iezza, E. Scalzulli, G. La Barba, A. Maggi, S. Russo, C. Elena, A.R. Scortechini, A. Tafuri, R. Latagliata, G. Caocci, M. Bocchia, S. Galimberti, L. Luciano, C. Fava, R. Foà, G. Saglio, G. Rosti, M. Breccia
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
2023 F. Palandri, G. Alberto Maria PALUMBO, M. Bonifacio, E. Maria Elli, M. Tiribelli, G. Auteri, M.M. Trawinska, N. Polverelli, G. Benevolo, A. Tieghi, F. Cavalca, G. Caocci, E. Beggiato, G. Binotto, F. Cavazzini, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, M. Venturi, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, E. Abruzzese, F. Branzanti, N. Vianelli, M. Cavo, F. Heidel, A. Iurlo, M. Breccia
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib
2023 A. Iurlo, N. Galli, C. Bucelli, S. Artuso, D. Consonni, D. Cattaneo
Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases
2023 V. Bellani, G.A. Croci, C. Bucelli, C.A. Maronese, S. Alberti, A. Iurlo, D. Cattaneo
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
2022 B. Mora, P. Guglielmelli, A. Kuykendall, E. Rumi, M. Maffioli, F. Palandri, V. De Stefano, M. Caramella, S. Salmoiraghi, J. Kiladjian, J. Gotlib, A. Iurlo, F. Cervantes, M. Ruggeri, R.T. Silver, F. Albano, G. Benevolo, D.M. Ross, M.G. Della Porta, T. Devos, G. Rotunno, R.S. Komrokji, I.C. Casetti, M. Merli, M. Brociner, D. Caramazza, G. Auteri, T. Barbui, D. Cattaneo, L. Bertù, L. Arcaini, A.M. Vannucchi, F. Passamonti
Breakthrough infections in MPN-COVID vaccinated patients
2022 T. Barbui, A. Carobbio, A. Ghirardi, A. Iurlo, V. De Stefano, M.A. Sobas, E. Rumi, E.M. Elli, F. Lunghi, M. Gasior Kabat, B. Cuevas, P. Guglielmelli, M. Bonifacio, M. Marchetti, A. Alvarez-Larran, L. Fox, M. Bellini, R. Daffini, G. Benevolo, G. Carreno-Tarragona, A. Patriarca, H.K. Al-Ali, M.M.M. Andrade-Campos, F. Palandri, C. Harrison, M.A. Foncillas, S. Osorio, S. Koschmieder, E. Magro Mazo, J. Kiladjian, E. Bolaños Calderón, F.H. Heidel, K. Quiroz Cervantes, M. Griesshammer, V. Garcia-Gutierrez, A.M. Sanchez, J.C. Hernandez-Boluda, E. Lopez Abadia, G. Carli, M. Sagues Serrano, R. Kusec, B. Xicoy Cirici, M. Guenova, B. Navas Elorza, A. Angona, E. Cichocka, A. Kulikowska de Nałęcz, D. Cattaneo, C. Bucelli, S. Betti, O. Borsani, F. Cavalca, S. Carbonell, N. Curto-Garcia, L. Benajiba, A. Rambaldi, A.M. Vannucchi